Gensight Biologics SA, of Paris, reported additional data after 78 weeks of follow-up in its phase I/II trial, confirming the safety and tolerability profile of GS010, while demonstrating sustainable visual acuity improvement in patients with Leber's hereditary optic neuropathy (LHON).